AU2007286203B2 - Multistage delivery of active agents - Google Patents

Multistage delivery of active agents Download PDF

Info

Publication number
AU2007286203B2
AU2007286203B2 AU2007286203A AU2007286203A AU2007286203B2 AU 2007286203 B2 AU2007286203 B2 AU 2007286203B2 AU 2007286203 A AU2007286203 A AU 2007286203A AU 2007286203 A AU2007286203 A AU 2007286203A AU 2007286203 B2 AU2007286203 B2 AU 2007286203B2
Authority
AU
Australia
Prior art keywords
stage
particle
particles
stage particle
barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007286203A
Other languages
English (en)
Other versions
AU2007286203A1 (en
AU2007286203A2 (en
Inventor
Mauro Ferrari
Jason Sakamoto
Ennio Tasciotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Ohio State University Research Foundation
Original Assignee
University of Texas System
University of Texas at Austin
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Ohio State University Research Foundation filed Critical University of Texas System
Publication of AU2007286203A1 publication Critical patent/AU2007286203A1/en
Assigned to TASCIOTTI, ENNIO, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM reassignment TASCIOTTI, ENNIO Alteration of Name(s) of Applicant(s) under S113 Assignors: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS, TASCIOTTI, ENNIO
Publication of AU2007286203A2 publication Critical patent/AU2007286203A2/en
Assigned to THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM reassignment THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION Alteration of Name(s) of Applicant(s) under S113 Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, TASCIOTTI, ENNIO
Application granted granted Critical
Publication of AU2007286203B2 publication Critical patent/AU2007286203B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007286203A 2006-08-08 2007-08-08 Multistage delivery of active agents Active AU2007286203B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82175006P 2006-08-08 2006-08-08
US60/821,750 2006-08-08
US91434807P 2007-04-27 2007-04-27
US60/914,348 2007-04-27
PCT/US2007/075516 WO2008021908A2 (en) 2006-08-08 2007-08-08 Multistage delivery of active agents

Publications (3)

Publication Number Publication Date
AU2007286203A1 AU2007286203A1 (en) 2008-02-21
AU2007286203A2 AU2007286203A2 (en) 2009-03-19
AU2007286203B2 true AU2007286203B2 (en) 2013-05-02

Family

ID=39082940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007286203A Active AU2007286203B2 (en) 2006-08-08 2007-08-08 Multistage delivery of active agents

Country Status (8)

Country Link
US (4) US20080311182A1 (https=)
EP (1) EP2056794A4 (https=)
JP (1) JP2010500375A (https=)
CN (1) CN101652126B (https=)
AU (1) AU2007286203B2 (https=)
CA (1) CA2664919A1 (https=)
MX (1) MX2009001461A (https=)
WO (1) WO2008021908A2 (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US7854944B2 (en) * 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
CA2648581A1 (en) 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
WO2008106350A1 (en) * 2007-02-26 2008-09-04 Board Of Regents Of The University Of Texas System Endocytotic particles
US8920625B2 (en) 2007-04-27 2014-12-30 Board Of Regents Of The University Of Texas System Electrochemical method of making porous particles using a constant current density
CA2722183C (en) * 2008-04-25 2018-09-18 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US8173115B2 (en) 2008-07-29 2012-05-08 The Board Of Regents Of The University Of Texas System Particle compositions with a pre-selected cell internalization mode
CA2732252A1 (en) * 2008-07-29 2010-02-04 Paolo Decuzzi Particle compositions with a pre-selected cell internalization mode
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
EP2373292A1 (en) * 2008-12-23 2011-10-12 Board of Regents of the University of Texas System Inflammation targeting particles
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20120045396A1 (en) * 2009-01-15 2012-02-23 Board Of Regents Of The University Of Texas System Porous structures with modified biodegradation kinetics
EP2398462A4 (en) * 2009-02-18 2012-07-25 Aradigm Corp PH-MODULATED FORMULATIONS FOR PULMONARY ADMINISTRATION
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
BRPI1011269A2 (pt) * 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
FR2948024B1 (fr) * 2009-07-17 2020-01-10 Centre National De La Recherche Scientifique - Cnrs - Emulsion activable par ultrasons et son procede de fabrication.
CA2775324C (en) * 2009-09-23 2018-05-15 Crystalplex Corporation Passivated nanoparticles
ES2367959B1 (es) * 2009-12-22 2013-01-24 Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina Particulas magnético-luminiscentes para aplicaciones biomédicas.
WO2011091065A2 (en) 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
CN102858367B (zh) 2010-02-26 2014-12-17 国立大学法人长崎大学 抗原或药物递送复合物
US8568877B2 (en) 2010-03-09 2013-10-29 Board Of Regents Of The University Of Texas System Porous and non-porous nanostructures
WO2011116237A1 (en) * 2010-03-17 2011-09-22 Board Of Regents Of The University Of Texas System Universal cell-directed theranostics
EP2590605A1 (en) 2010-07-09 2013-05-15 Board of Regents of the University of Texas System Biodegradable scaffolds
WO2012021922A1 (en) * 2010-08-16 2012-02-23 Australian Nuclear Science & Technology Organisation Particulate substances comprising ceramic particles for delivery of biomolecules
US20130224282A1 (en) * 2010-09-21 2013-08-29 Massachusetts Institute Of Technology Multistage Nanoparticles
RU2475233C2 (ru) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
EP2697162B1 (en) 2011-04-14 2020-12-02 The Regents of The University of California Multifunctional nanoparticle designs and applications
CN103998932B (zh) 2011-06-29 2017-06-06 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
US8859004B2 (en) 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
WO2013095736A2 (en) * 2011-09-27 2013-06-27 The Methodist Hospital Research Institute Gold-in-silicon nanoassembly for thermal therapy and methods of use
WO2013070872A1 (en) 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
US8926994B2 (en) * 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US20130304050A1 (en) * 2012-05-10 2013-11-14 Wake Forest University Health Sciences Methods of treating cancerous tissue
US10842749B2 (en) * 2012-06-12 2020-11-24 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
US8883216B2 (en) 2012-08-27 2014-11-11 Red Lion Chem Tech, Llc Methods and ceramic nanoparticle compositions for heavy metal removal and for oral delivery of desirable agents
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2912975A1 (en) * 2012-10-16 2014-04-24 William Marsh Rice University An improved nanovector based drug delivery system for overcoming drug resistance
US20170136123A1 (en) * 2013-01-10 2017-05-18 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
JP2015007209A (ja) * 2013-05-31 2015-01-15 株式会社リコー コアシェル型粒子、及びその製造方法
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
US20160279187A1 (en) * 2013-10-31 2016-09-29 University Of Hawaii Calpain inhibitors for ibd and colorectal cancer treatment
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
WO2015153816A2 (en) 2014-04-01 2015-10-08 Academia Sinica Methods and systems for cancer diagnosis and prognosis
WO2015176025A1 (en) 2014-05-15 2015-11-19 The Methodist Hospital Discoidal polymeric nanoconstructs and methods of use in cancer theranostics
EP3971262B1 (en) 2014-05-29 2024-04-24 Tectus Corporation Dispersion system for quantum dots
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3173074A4 (en) 2014-07-22 2018-03-07 Lemonex Inc. Composition for delivering bioactive material or protein, and use thereof
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
MX2017003903A (es) 2014-10-03 2017-09-15 Ntercept Llc Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
CA2963931A1 (en) 2014-10-06 2016-04-14 Exicure, Inc. Anti-tnf compounds
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
CN114533898B (zh) * 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
ITUB20159209A1 (it) 2015-12-21 2017-06-21 Fidia Farm Spa Nanosistemi per il trasporto controllato di molecole attive a fini diagnostici, prognostici e terapeutici
EP3426301A4 (en) * 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
US20190177615A1 (en) 2016-05-19 2019-06-13 Crystalplex Corporation Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3d structure containing them and methods of making and using them
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
KR20180091768A (ko) 2017-02-06 2018-08-16 주식회사 레모넥스 생리활성물질 전달체
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
JP2020526558A (ja) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
US20200163885A1 (en) * 2017-07-25 2020-05-28 Lemonex Inc. Composition for delivering physiologically active ingredients into blood vessel
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
KR102729931B1 (ko) 2017-12-19 2024-11-13 나노비오?笭? 신경 장애의 치료에서 사용하기 위한 나노입자
EP4461363A3 (en) 2017-12-19 2025-01-08 Nanobiotix Nanoparticles for use in enhancing brain performances or in treating stress
WO2019157319A1 (en) * 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN112546406B (zh) * 2020-11-20 2022-04-22 广东药科大学 一种微型机器人给药装置及给药系统
WO2024035784A1 (en) * 2022-08-10 2024-02-15 Auburn University Shrinking nanomaterial for biomedical applications

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20030059386A1 (en) * 2001-09-27 2003-03-27 Ceramoptec Industries, Inc. Topical application of chromophores for hair removal
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
WO2008054874A2 (en) * 2006-05-12 2008-05-08 Brown University Particles with high uniform loading of nanoparticles and methods of preparation thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US6099864A (en) 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
ES2130056B1 (es) * 1997-01-16 2000-02-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion.
WO2000030592A1 (en) * 1998-11-20 2000-06-02 The General Hospital Corporation Permanent, removable tissue markings
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US8753897B2 (en) 2005-12-20 2014-06-17 The Board Of Regents Of The University Of Texas System Nanoporous substrates for the analytical methods
WO2008041970A2 (en) * 2006-09-28 2008-04-10 Board Of Regents Of The University Of Texas System Methods and compositions for targeting fenestrated vasculature
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
US8920625B2 (en) * 2007-04-27 2014-12-30 Board Of Regents Of The University Of Texas System Electrochemical method of making porous particles using a constant current density

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
US20030059386A1 (en) * 2001-09-27 2003-03-27 Ceramoptec Industries, Inc. Topical application of chromophores for hair removal
WO2008054874A2 (en) * 2006-05-12 2008-05-08 Brown University Particles with high uniform loading of nanoparticles and methods of preparation thereof

Also Published As

Publication number Publication date
US20080311182A1 (en) 2008-12-18
CN101652126A (zh) 2010-02-17
EP2056794A2 (en) 2009-05-13
CN101652126B (zh) 2013-07-17
WO2008021908A2 (en) 2008-02-21
CA2664919A1 (en) 2008-02-21
US20160051481A1 (en) 2016-02-25
MX2009001461A (es) 2009-07-02
AU2007286203A1 (en) 2008-02-21
EP2056794A4 (en) 2012-12-26
AU2007286203A2 (en) 2009-03-19
HK1140139A1 (zh) 2010-10-08
WO2008021908A3 (en) 2008-08-14
US10143658B2 (en) 2018-12-04
US20190111000A1 (en) 2019-04-18
US20210338593A1 (en) 2021-11-04
JP2010500375A (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
US20210338593A1 (en) Multistage delivery of active agents
Ashfaq et al. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment
Li et al. Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy
A Santos et al. Multifunctional porous silicon for therapeutic drug delivery and imaging
Athar et al. Therapeutic nanoparticles: State-of-the-art of nanomedicine
Marciello et al. Freeze-dried cylinders carrying chitosan nanoparticles for vaginal peptide delivery
JP6894423B2 (ja) 融合性リポソーム被覆多孔質ケイ素ナノ粒子
Fattal et al. Nanomedicine technology: current achievements and new trends
Anoop et al. Approaches for encephalic drug delivery using nanomaterials: the current status
Son et al. Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration
Carissimi et al. Nanoparticles as drug delivery systems
CN104814934A (zh) 一种曲妥株单抗修饰的载紫杉醇的靶向纳米粒传递系统
Hnawate et al. Nanoparticle-novel drug delivery system: A Review
Chen et al. A dual-targeting nanocarrier based on modified chitosan micelles for tumor imaging and therapy
CN102264353A (zh) 炎症靶向颗粒
TWI483747B (zh) 口服式藥物載體及其製備方法
TWI472341B (zh) 寡聚物奈米顆粒複合體釋放系統
Wang et al. Optimization of landscape phage fusion protein-modified polymeric PEG-PE micelles for improved breast cancer cell targeting
Ferrari et al. Multistage delivery of active agents
Ahmad et al. Applications of nanotechnology in pharmaceutical development
GR et al. An overview of Nanocochleates for improving Oral absorption using a Phospolipid-based drug delivery system
Patel et al. Design and development of glutathione conjugated poly (d, l) lactide nanocarriers for delivery of hydrophilic fluorescent marker across blood brain barrier
Barbosa et al. Nanotechnology applied in drug delivery
HK1140139B (en) Multistage delivery of active agents
Kotha et al. Nanomaterials Mediated Diagnosis of Lung Cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 FEB 2009

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SAKAMOTO, JASON; TASCIOTTI, ENNIO AND FERRARI, MAURO .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FERRARI, MAURO; SAKAMOTO, JASON AND TASCIOTTI, ENNIO

FGA Letters patent sealed or granted (standard patent)